MHC-I peptide-binding groove presenting camyotope peptides (MHC-I-camyotope)

The MHC-I peptide-binding groove presenting camyotope peptides is a specialized molecular complex found on the surface of cancer cells, particularly in colorectal cancer. Camyotopes are a novel class of immunogenic epitopes derived from camyopeptides, which are translated from small open reading frames (smORFs) located within long non-coding RNAs (lncRNAs) that are specifically overexpressed in tumors (1.1.1, 1.2.1). These peptides are processed by the cellular machinery and loaded into the peptide-binding groove of Major Histocompatibility Complex Class I (MHC-I) molecules for presentation to CD8+ T cells (1.1.2). Because these lncRNA-derived antigens are highly tumor-specific and shared across many patients, they represent a potent off-the-shelf target for immunotherapy (1.2.2). Therapeutic strategies targeting this complex include mRNA-based vaccines, such as CAMYO-01, and TCR-engineered T-cell therapies designed to recognize the specific peptide-MHC (pMHC) configuration and trigger a robust anti-tumor immune response (1.1.3, 1.2.2). Unlike traditional neoantigens that arise from random mutations, camyotopes are derived from non-coding regions of the genome that become transcriptionally active in cancer, offering a broader and more consistent therapeutic reach across patient populations with compatible HLA alleles (1.2.1).

Other names

Camyotope-MHC complexlncRNA-derived neoantigen-MHC complexpMHC-camyotopeHLA-camyotope complex

Induction of a targeted CD8+ T-cell immune response against tumor cells by presenting tumor-specific, lncRNA-derived peptides (camyotopes) within the MHC-I groove to T-cell receptors (TCRs).